Cell and Gene Logistics

  1. Single-Use Solutions: Cell Growth 1/21/2026

    From early-stage research to commercial-scale production, Charter Medical delivers integrated solutions that streamline your biopharma workflows.

  2. Single-Use Solutions: Cryopreservation 1/20/2026

    As advanced therapy manufacturing evolves, maintaining the integrity of biological materials during cryopreservation steps is ever more critical.

  3. DEHP-Free CryoProtect™ Bio-Containers 1/18/2026

    Charter Medical’s DEHP-free CryoProtect™ Bio-Containers are designed for intermediate, final fill, storage, and transport in bioprocessing applications using compatible freezing cassettes.

  4. Cell Freeze® Cryogenic Storage Containers 1/17/2026

    Charter Medical’s Cell Freeze® cryogenic storage containers are designed for storage, preservation, and transfer of hematopoietic cells (HPC) in liquid nitrogen to -196ºC. The Cell Freeze® Liquid Nitrogen Freezing Container is provided sterile (fluid path) by gamma irradiation and intended for single use. Do not reuse. Reuse causes contamination of the interior fluid path.

  5. Moving Leukopaks From GTP To GMP Is One Cell Therapy Trend To Watch In '26 1/9/2026

    Cell therapy stumbled in 2025. Solving the variability in starting material quality is critical to stabilizing manufacturing in 2026.

  6. Global Shifts And Strategic Resilience Will Shape CGT In 2026 1/7/2026

    Dr. Miguel Forte, CEO of Kiji Therapeutics and President of ISCT, and Ali Pashazadeh, Founder of Treehill Partners share why CGT developers are now navigating a landscape defined not only by technological innovation but also by geography, regulatory agility, and investment dynamics.

  7. A Deeper Look At Pharma's Structural Supply Chain Vulnerability 12/31/2025

    Fixing limited capacity in pharmaceutical CMC development starts with understanding a complex web of root causes.

  8. What Is ISO 21973 And Why It Matters For Cell And Gene Therapy 12/29/2025

    ISO 21973 establishes global best practices for transporting cell and gene therapies, ensuring quality, safety, and consistency across complex supply chains critical to patient outcomes.

  9. Scaling For What's Next In EMEA 12/29/2025

    Scaling cell and gene therapy operations in EMEA demands strategic planning, regulatory alignment, and robust logistics to meet growing demand and ensure consistent delivery across diverse markets.

  10. Setting The Benchmark For Quality In Cell And Gene Therapy Logistics 12/29/2025

    ISO 21973 defines global best practices for transporting cell and gene therapies, ensuring safety, quality, and consistency across complex supply chains vital to patient care.